The IVORY trial, a randomized, placebo-controlled study, demonstrated that low-dose IL-2 administration in patients with acute coronary syndrome (ACS) resulted in a significant reduction in arterial inflammation, as assessed by 18F-FDG PET/CT imaging. Here, IL2 is linked to acute coronary syndrome.